Peptidoglycan recognition protein 4 (PGLYRP4)

Peptidoglycan recognition protein 4 (PGLYRP4) is a secreted pattern recognition receptor and innate immunity protein encoded by the PGLYRP4 gene in humans[1][3]. It belongs to the peptidoglycan recognition protein (PGRP) family, which recognizes and binds the peptidoglycan component of bacterial cell walls, especially those from Gram-positive bacteria, leading to antibacterial and anti-inflammatory effects[1][3][7]. PGLYRP4 is glycosylated, forms disulfide-linked homodimers or heterodimers (with PGLYRP3), and binds bacterial peptidoglycan with higher affinity for Gram-positive cocci cell wall fragments[1][3][5]. By binding and distorting bacterial peptidoglycan, PGLYRP4 disrupts cell wall maturation and exhibits bactericidal activity, playing an important role in the innate immune defense against bacterial infection. It has also been associated with certain inflammatory diseases, such as trigonitis and psoriasis[3]. There are no known drugs that directly target PGLYRP4, and no current biomarker or safety concerns described for therapeutic targeting.

Other names

PGRP-IβPGRP-IBPGRPIβ

Not a direct drug target as of current knowledge; bactericidal mechanism involves direct binding to bacterial peptidoglycan, disrupting cell wall maturation similar to glycopeptide antibiotics[1][3][7].